{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "ABBV-951 Treatment Arm",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "All subjects receive an oral loading dose of LD+DDCI followed by a 24-hour daily continuous subcutaneous infusion (CSCI) of ABBV-951. The dose is individualized and titrated during an Optimization Period to achieve optimal clinical response.",
        "extensionAttributes": [
          {
            "url": "x-titration",
            "valueString": "true"
          },
          {
            "url": "x-doseEpochs",
            "valueString": "[{'dose': 'Individualized (Starting rate F1 based on baseline LED)', 'startDay': 1, 'endDay': 28, 'description': 'Optimization Period: Weekly adjustments to ABBV-951 and concomitant PD medications to reach optimal clinical response.'}, {'dose': 'Optimal therapeutic dose', 'startDay': 29, 'endDay': 364, 'description': 'Maintenance Period: 48 weeks of continuous infusion at the optimized dose.'}]"
          }
        ]
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "ABBV-951 Treatment Arm - Screening Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for ABBV-951 Treatment Arm during Screening Period"
      },
      {
        "id": "elem_2",
        "name": "ABBV-951 Treatment Arm - Optimization Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for ABBV-951 Treatment Arm during Optimization Period"
      },
      {
        "id": "elem_3",
        "name": "ABBV-951 Treatment Arm - Maintenance Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for ABBV-951 Treatment Arm during Maintenance Period"
      },
      {
        "id": "elem_4",
        "name": "ABBV-951 Treatment Arm - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for ABBV-951 Treatment Arm during Follow-up"
      }
    ],
    "summary": {
      "armCount": 1,
      "cellCount": 4,
      "cohortCount": 0,
      "elementCount": 4
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Non-Randomized",
        "codeSystem": "USDM",
        "decode": "Non-Randomized"
      },
      "armIds": [
        "arm_1"
      ],
      "therapeuticAreas": [
        "Neurology",
        "Parkinson's Disease"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Non-Randomized",
        "allocationRatio": null,
        "stratificationFactors": []
      },
      "controlType": null,
      "therapeuticAreas": [
        "Neurology",
        "Parkinson's Disease"
      ]
    },
    "arms": [
      {
        "name": "ABBV-951 Treatment Arm",
        "type": "Experimental Arm",
        "description": "All subjects receive an oral loading dose of LD+DDCI followed by a 24-hour daily continuous subcutaneous infusion (CSCI) of ABBV-951. The dose is individualized and titrated during an Optimization Period to achieve optimal clinical response.",
        "isTitration": true,
        "doseEpochs": [
          {
            "dose": "Individualized (Starting rate F1 based on baseline LED)",
            "startDay": 1,
            "endDay": 28,
            "description": "Optimization Period: Weekly adjustments to ABBV-951 and concomitant PD medications to reach optimal clinical response."
          },
          {
            "dose": "Optimal therapeutic dose",
            "startDay": 29,
            "endDay": 364,
            "description": "Maintenance Period: 48 weeks of continuous infusion at the optimized dose."
          }
        ]
      }
    ],
    "cohorts": [],
    "epochs": [
      {
        "name": "Screening Period",
        "description": "10 to 42 days (up to 90 days), including a 6-day Monitoring Period for PD Diary and wearable device baseline."
      },
      {
        "name": "Optimization Period",
        "description": "Weeks 1-4 (Days 1-28); dose titration of ABBV-951 and adjustment of concomitant PD medications."
      },
      {
        "name": "Maintenance Period",
        "description": "Weeks 5-52 (Days 29-364); continuous infusion at stable optimal dose."
      },
      {
        "name": "Follow-up",
        "description": "30-day follow-up call after the end of infusion for subjects not entering the extension study."
      }
    ]
  }
}